Literature DB >> 28854621

A search for the "Goldilocks zone" with regard to the optimal duration of adjuvant temozolomide in patients with glioblastoma.

Stuart A Grossman1, Lawrence Kleinberg1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28854621      PMCID： PMC5570136          DOI： 10.1093/neuonc/nox046

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  9 in total

1.  Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: a Southeastern Cancer Study Group protocol.

Authors:  L H Einhorn; S D Williams; P J Loehrer; R Birch; R Drasga; G Omura; F A Greco
Journal:  J Clin Oncol       Date:  1989-03       Impact factor: 44.544

2.  Randomized trial of CVPP for three versus six cycles in favorable-prognosis and CVPP versus AOPE plus radiotherapy in intermediate-prognosis untreated Hodgkin's disease.

Authors:  S Pavlovsky; E Schvartzman; F Lastiri; H Magnasco; C Corrado; E Raslawski; M E Cancela; M C Ardaiz; I Cerutti; A Rosso; S Bruno; P N Aranguren; A Salvarezza; H Donato; E Dibar; S Zirone
Journal:  J Clin Oncol       Date:  1997-07       Impact factor: 44.544

3.  Six cycles of doxorubicin and cyclophosphamide or Paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101.

Authors:  Lawrence N Shulman; Constance T Cirrincione; Donald A Berry; Heather P Becker; Edith A Perez; Ruth O'Regan; Silvana Martino; James N Atkins; Erica Mayer; Charles J Schneider; Gretchen Kimmick; Larry Norton; Hyman Muss; Eric P Winer; Clifford Hudis
Journal:  J Clin Oncol       Date:  2012-07-23       Impact factor: 44.544

4.  Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma.

Authors:  T B Hakes; E Chalas; W J Hoskins; W B Jones; M Markman; S C Rubin; D Chapman; L Almadrones; J L Lewis
Journal:  Gynecol Oncol       Date:  1992-06       Impact factor: 5.482

5.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.

Authors:  Roger Stupp; Warren P Mason; Martin J van den Bent; Michael Weller; Barbara Fisher; Martin J B Taphoorn; Karl Belanger; Alba A Brandes; Christine Marosi; Ulrich Bogdahn; Jürgen Curschmann; Robert C Janzer; Samuel K Ludwin; Thierry Gorlia; Anouk Allgeier; Denis Lacombe; J Gregory Cairncross; Elizabeth Eisenhauer; René O Mirimanoff
Journal:  N Engl J Med       Date:  2005-03-10       Impact factor: 91.245

Review 6.  Duration of adjuvant chemotherapy for patients with non-metastatic colorectal cancer.

Authors:  Gaëtan Des Guetz; Bernard Uzzan; Jean-Francois Morere; Gerard Perret; Patrick Nicolas
Journal:  Cochrane Database Syst Rev       Date:  2010-01-20

7.  Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial.

Authors:  Mark R Gilbert; Meihua Wang; Kenneth D Aldape; Roger Stupp; Monika E Hegi; Kurt A Jaeckle; Terri S Armstrong; Jeffrey S Wefel; Minhee Won; Deborah T Blumenthal; Anita Mahajan; Christopher J Schultz; Sara Erridge; Brigitta Baumert; Kristen I Hopkins; Tzahala Tzuk-Shina; Paul D Brown; Arnab Chakravarti; Walter J Curran; Minesh P Mehta
Journal:  J Clin Oncol       Date:  2013-10-07       Impact factor: 44.544

8.  Optimal duration of fluorouracil-based adjuvant chemotherapy for patients with resectable gastric cancer.

Authors:  Jing-lei Qu; Xin Li; Xiu-Juan Qu; Zhi-tu Zhu; Li-zhong Zhou; Yue-e Teng; Jing-dong Zhang; Bo Jin; Ming-fang Zhao; Ping Yu; Yun-peng Liu
Journal:  PLoS One       Date:  2013-12-26       Impact factor: 3.240

9.  Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG.

Authors:  Deborah T Blumenthal; Thierry Gorlia; Mark R Gilbert; Michelle M Kim; L Burt Nabors; Warren P Mason; Monika E Hegi; Peixin Zhang; Vassilis Golfinopoulos; James R Perry; Do Hyun Nam; Sara C Erridge; Benjamin W Corn; René O Mirimanoff; Paul D Brown; Brigitta G Baumert; Minesh P Mehta; Martin J van den Bent; David A Reardon; Michael Weller; Roger Stupp
Journal:  Neuro Oncol       Date:  2017-08-01       Impact factor: 12.300
  9 in total
  1 in total

1.  M1 muscarinic receptor is a key target of neuroprotection, neuroregeneration and memory recovery by i-Extract from Withania somnifera.

Authors:  Arpita Konar; Richa Gupta; Rajendra K Shukla; Bryan Maloney; Vinay K Khanna; Renu Wadhwa; Debomoy K Lahiri; Mahendra K Thakur
Journal:  Sci Rep       Date:  2019-09-30       Impact factor: 4.379
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.